Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Teases Big Cancer Drug Readouts In Second Half

Jul 30 2021

• By Alaric DeArment

Cancer cells on scientific background.3d illustration — Gilead announced its second quarter earnings, highlighting developments in virology as well as oncology • Source: Shutterstock

Related Content

Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Jun 24 2021

BMS Sighs In Relief As Opdivo Returns To Sales Growth

Jul 28 2021

BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets

Jul 19 2021

Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

Jul 29 2021

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

May 27 2020

Related Companies

Gilead Sciences, Inc.

Bristol Myers Squibb Company

BioNTech SE

Arcus Biosciences, Inc.

Merck & Co., Inc.

Roche Holding AG

Additional Topics

Sales & Earnings Clinical Trials Commercial Cancer BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.